Pegasys market share
Executive Summary
Roche Pegasys share of new prescriptions is 26% in the U.S. for the first quarter, up from 23% at the end of 2002, company tells analyst call April 10. The hepatitis C therapy may get a boost from the 15,000 patients who received peginterferon alfa-2a for three months free of charge ahead of the Copegus combination approval (1"The Pink Sheet" Oct. 21, 2002, p. 10)...
You may also be interested in...
Roche Pegasys Has $291 WAC; Launch Includes 12 Weeks Of Free Samples
Roche's Pegasys has a wholesale acquisition cost of $291 for one week of the hepatitis C therapy
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: